Zobrazeno 1 - 10
of 1 274
pro vyhledávání: '"Hermann Einsele"'
Autor:
Adrian-Bogdan Tigu, Raluca Munteanu, Cristian Moldovan, Drula Rares, David Kegyes, Radu Tomai, Vlad Moisoiu, Gabriel Ghiaur, Ciprian Tomuleasa, Hermann Einsele, Diana Gulei, Carlo M. Croce
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-13 (2024)
Abstract Receptor tyrosine kinases (RTKs) are key cell surface receptors involved in cell communication and signal transduction, with great importance in cell growth, differentiation, survival, and metabolism. Dysregulation of RTKs, such as EGFR, VEG
Externí odkaz:
https://doaj.org/article/c92b9a0c66d743f0a6597e40769c6711
Autor:
Ciprian Tomuleasa, Adrian-Bogdan Tigu, Raluca Munteanu, Cristian-Silviu Moldovan, David Kegyes, Anca Onaciu, Diana Gulei, Gabriel Ghiaur, Hermann Einsele, Carlo M. Croce
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-51 (2024)
Abstract Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and o
Externí odkaz:
https://doaj.org/article/0776fe4bbdb94fc08ad9c64a0cef2914
Autor:
Umair Munawar, Johanna Theuersbacher, Maximilian J. Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S. Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K. Martin Kortüm, Johannes M. Waldschmidt
Publikováno v:
Haematologica, Vol 109, Iss 11 (2024)
Externí odkaz:
https://doaj.org/article/09c3d7b2071d4832b1033ee4fc16cf6d
Autor:
Xiang Zhou, Patrick Costello, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Max Topp, Hartmut Goldschmidt, Hermann Einsele, Nikhil C Munshi, Marc S Raab, Joseph Kauer, Thomas Hielscher, Niels Weinhold, Mirco J Friedrich, Sandra Sauer, Leo Rasche, Thomas Luft, Jan H Frenking, Vivien Wagner, Elias K Mai, Christian S Michel, Marina Hajiyianni, Iris Breitkreutz, Omar Nadeem, Adam S Sperling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine re
Externí odkaz:
https://doaj.org/article/8940433ced884d68a993840e8bd1f4cb
Autor:
Sandra Michaela Ihne-Schubert, Teresa Radovic, Saskia Fries, Stefan Frantz, Hermann Einsele, Stefan Störk, Silke Neuderth
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Amyloidosis represents a rare yet heterogeneous multi-system disorder associated with a grave prognosis and an enormous psycho-emotional strain on patients, relatives, and caregivers. We here present the overall study design and f
Externí odkaz:
https://doaj.org/article/cb61198f63f946e5a4e879ad7cf1d062
Autor:
Umair Munawar, Xiang Zhou, Sabrina Prommersberger, Silvia Nerreter, Cornelia Vogt, Maximilian J. Steinhardt, Marietta Truger, Julia Mersi, Eva Teufel, Seungbin Han, Larissa Haertle, Nicole Banholzer, Patrick Eiring, Sophia Danhof, Miguel Angel Navarro-Aguadero, Adrian Fernandez-Martin, Alejandra Ortiz-Ruiz, Santiago Barrio, Miguel Gallardo, Antonio Valeri, Eva Castellano, Peter Raab, Maximilian Rudert, Claudia Haferlach, Markus Sauer, Michael Hudecek, J. Martinez-Lopez, Johannes Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-9 (2023)
Abstract The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms
Externí odkaz:
https://doaj.org/article/91aba52b6c244a118ef7a4278eff963f
Autor:
David Baden, Sven Zukunft, Gema Hernandez, Nadine Wolgast, Sophie Steinhauser, Alexander Pohlmann, Christoph Schliemann, Jan-Henrik Mikesch, Bjorn Steffen, Tim Sauer, Maher Hanoun, Kerstin Schafer-Eckart, Stefan W. Krause, Mathias Hanel, Hermann Einsele, Edgar Jost, Tim H. Brummendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer, Andreas Burchert, Martin Kaufmann, Dirk Niemann, Markus Schaich, Wolfgang Blau, Alexander Kiani, Martin Gorner, Ulrich Kaiser, Johannes Kullmer, Thomas Weber, Wolfgang E Berdel, Gerhard Ehninger, Carsten Muller-Tidow, Uwe Platzbecker, Hubert Serve, Martin Bornhauser, Christoph Rollig, Claudia D Baldus, Lars Fransecky
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
In newly diagnosed acute myeloid leukemia, immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pre-therapeutic risk factors. We explored the impact of time from
Externí odkaz:
https://doaj.org/article/a18a7d664edd4e4590ac8fdec959dd27
Autor:
Umair Munawar, Johanna Theuersbacher, Maximilian J. Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S. Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K. Martin Kortüm, Johannes M. Waldschmidt
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for patients ineligible for CAR-T and bispecific a
Externí odkaz:
https://doaj.org/article/5b70ffdb59ff4ed5b400827482becc1e
Autor:
Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina Patel, Karthik Ramasamy, Maria-Victoria Mateos
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-17 (2023)
Abstract Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is a
Externí odkaz:
https://doaj.org/article/9cc1745b33414a3f8f0955517dbe626e
Autor:
Sandra Michaela Ihne-Schubert, Maria Leberzammer, Marcel Weidgans, Stefan Frantz, Hermann Einsele, Stefan Knop, Torben Schubert, Tanja Bratan, Stefan Störk, Silke Neuderth
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0297182 (2024)
BackgroundAmyloidosis is a rare multi-system disorder associated with frequently delayed diagnosis, enormous disease burden and psychosocial distress.MethodsSystematic assessment of needs was performed by a subtype-spanning questionnaire-based survey
Externí odkaz:
https://doaj.org/article/b8028af14da94d4b86b9bf3cebf92cc0